Head-to-head evidence
HMS1005 vs SY-004
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: Glucokinase · full Type 2 Diabetes pipeline
HMS1005
Developed by Hua Medicine
NCT06498284 · Phase 1 · completed
The trial randomized participants against a matched placebo with both participants and investigators blinded, but the primary measures were safety and drug levels rather than a validated diabetes outcome like HbA1c. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
The sponsor release does not cite the trial's registry number; identity rests on the matching sponsor, drug code, country, design and enrollment.
SY-004
Developed by Suzhou Yabao Pharmaceutical
NCT04217291 · Phase 2 · completed
The trial was randomized, quadruple-blind, placebo-controlled, and enrolled 200 participants, but its primary endpoint was the surrogate measure of change in HbA1c rather than a hard clinical outcome. Because the registry does not report whether the primary comparison was favorable or statistically significant, the evidence is limited to a moderate grade.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: HMS1005's landscape · SY-004's landscape